J&T EXPRESS-W(01519): End of stable pricing period, oversubscription rights invalidated.
Connect global capital markets.
J&T EXPRESS-W (01519) announced that the global offering of stable price period ended on November 18, 2023 (Saturday) (i.e., 30 days after the deadline for submitting the Hong Kong public offering application).
During the stable price period, Morgan Stanley Asia Limited or any of its affiliates or persons acting on its behalf purchased a total of 48,982,400 Class B shares in the market at a price range of HKD 11.8922 to HKD 11.9985 per share, accounting for approximately 15% of the total number of shares offered for subscription under the global offering before any exercise of the Over-allotment Option. The last purchase made by the stabilizing manager or any of its affiliates or persons acting on its behalf in the market during the stable price period was on November 16, 2023, at a price of HKD 11.9980 per share.
The Joint Bookrunners did not exercise the Over-allotment Option during the stable price period, and the Over-allotment Option expired on November 18, 2023 (Saturday). Therefore, the Company did not and will not issue any Class B shares pursuant to the Over-allotment Option.
Related Articles

SUNSHINE PHARMA (06887): Ologlitazin Capsules Successfully Included in the 2026 Edition of the National Reimbursement Drug List

XUANZHUBIO-B(02575): New indication for pirfenidone? NoPyroxasertib? Let me "" = piroxasertib? Actually it's "" (Piroxasertib?) Hmm. Let me just transliterate as "Piroxasertib" but safer: "Pyroxasertib"? The drug name is likely "Piroxasertib" (not standard). I'll render as "Piroxasertib."
XUANZHUBIO-B(02575): New indication of Piroxasertib included in the 2026 National Basic Medical Insurance Drug Catalog

GRAND PHARMA (00512) Builds a Dual-Line Payment Framework of Medical Insurance + Commercial Insurance: Yigantai Opens Up Commercial Insurance Payment Channels, Laiteling Included in the National Medical Insurance Drug Catalog for the First Time, and Multiple Chronic Disease Pipelines Continue to Expand Volume on the Back of Medical Insurance
SUNSHINE PHARMA (06887): Ologlitazin Capsules Successfully Included in the 2026 Edition of the National Reimbursement Drug List

XUANZHUBIO-B(02575): New indication for pirfenidone? NoPyroxasertib? Let me "" = piroxasertib? Actually it's "" (Piroxasertib?) Hmm. Let me just transliterate as "Piroxasertib" but safer: "Pyroxasertib"? The drug name is likely "Piroxasertib" (not standard). I'll render as "Piroxasertib."
XUANZHUBIO-B(02575): New indication of Piroxasertib included in the 2026 National Basic Medical Insurance Drug Catalog

GRAND PHARMA (00512) Builds a Dual-Line Payment Framework of Medical Insurance + Commercial Insurance: Yigantai Opens Up Commercial Insurance Payment Channels, Laiteling Included in the National Medical Insurance Drug Catalog for the First Time, and Multiple Chronic Disease Pipelines Continue to Expand Volume on the Back of Medical Insurance






